Moderna Inc (MRNA)

[axelvento]

In the fall vaccination season, Moderna captured 48% of the COVID-19 retail market in the United States versus a 37% showing in 2022, closing the gap on Pfizer’s Comirnaty

Much of the call was focused on Moderna’s respiratory syncytial virus (RSV) vaccine, which is lined up for an FDA decision in May. The company appears poised to join a market competition with GSK’s Arexvy and Pfizer’s Abrysvo, which achieved 2023 sales of $1.5 billion and $890 million, respectively, in their first year on the market for people ages 60 and older.

The company sees the RSV market booming to $10 billion, with sales of between $6 billion to $8 billion in the older adult population.

https://www.fiercepharma.com/pharma/while-moderna-moving-covid-its-vaccine-gaining-share-pfizers-comirnaty